Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × tremelimumab × Gastrointestinal × Clear all

Status

Sponsor Class

Study Type

Interventional 78 Observational 1

Sponsor

Cancer Type

Dermatologic 2 Thoracic 1 Other neoplasm 1 Genitourinary 1 Gastrointestinal 1

Conditions

Unresectable Hepatocellular Carcinoma 1

Interventions

Blood Specimen Collection 81 Surveys and Questionnaires 73 Surgical Procedures, Operative 43 Drug Therapy 40 Bevacizumab 37 Observation 36 Colonoscopy 34 Biopsy 29 Hepatectomy 28 Neoadjuvant Therapy 25 Immune Checkpoint Inhibitors 25 Radiotherapy 23 Capecitabine 23 Oxaliplatin 22 Interviews as Topic 22 regorafenib 21 Magnetic Resonance Spectroscopy 20 Endoscopic Mucosal Resection 19 lenvatinib 18 Specimen Handling 17 Liquid Biopsy 17 Immunohistochemistry 17 Sorafenib 16 Gastroscopy 16 Gastrectomy 16 Pancreaticoduodenectomy 14 Endoscopic Ultrasound-Guided Fine Needle Aspiration 14 Tomography, X-Ray Computed 13 Nivolumab 13 Fluorouracil 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06117891 2025-11-12

REFINE-IO

Bayer

Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡